Tweet
Bellevue Group AG decreased its holdings in shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 12.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 79,900 shares of the biopharmaceutical company's stock after selling 11,100 shares during the quarter. Bellevue Group AG's holdings in Intra-Cellular Therapies were worth $1,412,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wasatch Advisors Inc. boosted its holdings in Intra-Cellular Therapies by 1.4% during the second quarter. Wasatch Advisors Inc. now owns 1,908,231 shares of the biopharmaceutical company's stock worth $33,718,000 after purchasing an additional 25,889 shares during the last quarter. PointState Capital LP acquired a new position in Intra-Cellular Therapies during the first quarter worth $39,334,000. Columbus Circle Investors boosted its holdings in Intra-Cellular Therapies by 72.2% during the first quarter. Columbus Circle Investors now owns 556,156 shares of the biopharmaceutical company's stock worth $11,707,000 after purchasing an additional 233,107 shares during the last quarter. Northern Trust Corp boosted its holdings in Intra-Cellular Therapies by 1.6% during the first quarter. Northern Trust Corp now owns 493,563 shares of the biopharmaceutical company's stock worth $10,390,000 after purchasing an additional 7,598 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Intra-Cellular Therapies by 2.9% during the first quarter. Schwab Charles Investment Management Inc. now owns 227,798 shares of the biopharmaceutical company's stock worth $4,796,000 after purchasing an additional 6,357 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock. Get Intra-Cellular Therapies alerts:
Several research analysts recently commented on the stock. Canaccord Genuity set a $31.00 target price on shares of Intra-Cellular Therapies and gave the stock a "buy" rating in a report on Thursday, August 2nd. ValuEngine cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating in a report on Wednesday, June 27th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a "sell" rating to a "hold" rating in a report on Tuesday, May 8th. Cantor Fitzgerald restated a "buy" rating and set a $28.00 target price on shares of Intra-Cellular Therapies in a report on Monday, July 23rd. Finally, BidaskClub cut shares of Intra-Cellular Therapies from a "hold" rating to a "sell" rating in a research note on Saturday, April 28th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Intra-Cellular Therapies currently has an average rating of "Buy" and an average price target of $28.45. Shares of ITCI stock opened at $19.57 on Friday. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -9.23 and a beta of 0.81. Intra-Cellular Therapies Inc has a one year low of $10.82 and a one year high of $25.82.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.08. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 31.73%. equities research analysts expect that Intra-Cellular Therapies Inc will post -3.2 EPS for the current year.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
See Also: Earnings Per Share (EPS) Explained
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI). Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter 